test

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Conditions

Breast - Female | Breast - Male | Cancer

What is the purpose of this trial?

The primary objective of this study is to compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer.


Participation Guidelines

Age:
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Southwest Oncology Group (SWOG)
Dates:
10/10/2013
Last Updated:
Study HIC#:
1304011806